| __timestamp | Neurocrine Biosciences, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 55430000 |
| Thursday, January 1, 2015 | 81491000 | 65510000 |
| Friday, January 1, 2016 | 94291000 | 71160000 |
| Sunday, January 1, 2017 | 121827000 | 70644000 |
| Monday, January 1, 2018 | 160524000 | 70418000 |
| Tuesday, January 1, 2019 | 200000000 | 63238000 |
| Wednesday, January 1, 2020 | 275000000 | 59777000 |
| Friday, January 1, 2021 | 328100000 | 60152000 |
| Saturday, January 1, 2022 | 463800000 | 54540000 |
| Sunday, January 1, 2023 | 565000000 | 52243000 |
| Monday, January 1, 2024 | 731100000 | 64536000 |
Unleashing insights
In the competitive landscape of pharmaceuticals, research and development (R&D) investment is a critical driver of innovation and growth. Over the past decade, Neurocrine Biosciences, Inc. has significantly ramped up its R&D spending, showcasing a remarkable increase of over 1,100% from 2014 to 2023. This strategic focus on innovation is evident as their R&D expenses surged from approximately $46 million in 2014 to an impressive $565 million in 2023. In contrast, Taro Pharmaceutical Industries Ltd. maintained a more consistent R&D investment, with a modest 17% increase over the same period, peaking at around $71 million in 2016. This disparity highlights Neurocrine's aggressive pursuit of new therapies and market leadership. As we look to the future, the absence of 2024 data for Neurocrine suggests a potential shift or recalibration in their R&D strategy, while Taro's steady investment continues to reflect its stable approach.
Who Prioritizes Innovation? R&D Spending Compared for Eli Lilly and Company and Taro Pharmaceutical Industries Ltd.
R&D Insights: How Novo Nordisk A/S and Taro Pharmaceutical Industries Ltd. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Vertex Pharmaceuticals Incorporated and Taro Pharmaceutical Industries Ltd.
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
Takeda Pharmaceutical Company Limited or Taro Pharmaceutical Industries Ltd.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Summit Therapeutics Inc. and Taro Pharmaceutical Industries Ltd.